Saluda Medical earned FDA approval for its biomarker-based automated patient programming platform used in spinal cord stimulation.

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

Now, a new crop of buzzy non-invasive VNS gadgets promises to relieve stress, sharpen focus and improve sleep in mere minutes ...

Nalu Medical announced today that the FDA cleared expanded labeling of its peripheral nerve system to include whole-body MRI ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data supports the ...

"The nice thing about vagus nerve stimulation, we know from other studies, is that when the patient responds, the effects usually stick," says Conway.

Why Trust Us? “Muscle stimulators do exactly what they promise—stimulate muscles,” Lori Diamos, M.S., P.T., owner of PT Pearls in Chicago tells us. Via a series of carefully placed ...

Inspire has developed a neurostimulation ... The Agency could require further proof that bilateral hypoglossal nerve stimulation is safe and consistently effective. The external patch needs ...